Diabetic Retinopathy (DR) and Diabetic
Macular Edema (DME) can put your
patients at risk of vision loss1

DR: A Common, Serious, and Undertreated Complication of Diabetes2,3

See a
DR Severity

DME Is a Complication of DR That Can Occur Any Time5

Half the patients newly diagnosed with DME present with visual acuity of worse than 20/406

  • About half the people with DR are expected to develop DME1
  • Risk of DME increases with the severity of DR1
Half of newly diagnosed Diabetic Macular Edema patients present with worse than 20/40 visual acuity

Awareness Is Limited Among Patients With Diabetic Eye Disease7

The AOA states that in 2017 alone, Doctors of Optometry diagnosed >400,000 new cases of
DR.8 And, in a 2014 study, the majority of patients with DR or DME reported that they had
never been told by a doctor that diabetes was affecting their eyes.9

% Patients With DME or DR Without DME Not Told by a Doctor That Diabetes Was Affecting Their Eyes

In a survey of 798 patients, 55% of patients with DME and 74% of patients with DR reported that they had never been told by a doctor that diabetes was affecting their eyes

% Patients


Patients with DME


Patients with DR

Cross-sectional analysis of 2005-2008 National Health and Nutrition Examination Survey (NHANES) national data; N=798 participants with self-reported diabetes stratified by DR and DME status.

There is a significant need for diabetes patient education9

The Majority of Patients at Risk of Vision Loss From Severe
Nonproliferative DR (NPDR) Without DME Are Not Being Treated10

In a Retrospective Analysis Conducted by Regeneron, Many Commercially Insured
Patients With DR Without DME Were Untreated 1 Year Following Diagnosis (age ≥18 years; N=9633)10

95% of patients with mild Nonproliferative Diabetic Retinopathy, 77% of patients with moderate NPDR, and 60% of patients with severe NPDR were untreated one year following diagnosis

% Patients With Untreated DR




Moderate NPDR


Severe NPDR

Data on file—Results of a retrospective longitudinal cohort analysis of Truven MarketScan Commercial and Medicare claims data. Patients were included in the analysis if they were aged ≥18 years, had a diagnosis of diabetes, and had a diagnosis of DR without macular edema. Patients categorized according to most severe DR diagnosis (order: severe NPDR, moderate NPDR, mild NPDR). Study period: January 1, 2015, through December 31, 2015.

You play an important role in educating patients with diabetes about modifiable
risk factors for the development and progression of DR and DME. These include11:

  • Diet and weight
  • Tobacco use
  • Obstructive sleep apnea
  • High blood pressure
  • High cholesterol and triglyceride levels

Your Diabetes Patients May Be at Serious Risk of Vision Loss.

AOA = American Optometric Association; CDC = Centers for Disease Control and Prevention.

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information and Indications INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.


  1. Diabetic Retinopathy. National Eye Institute, National Institutes of Health website. http://bit.ly/2JLRRLW. Accessed January 14, 2020.
  2. Common Eye Disorders. Centers for Disease Control and Prevention website. http://bit.ly/2YNSBFA. Accessed January 14, 2020.
  3. Diabetic Retinopathy. Centers for Disease Control and Prevention website. http://bit.ly/2BKTVCTS. Accessed January 14, 2020.
  4. Number of Americans With Diabetes Projected to Double or Triple by 2050 [press release]. Centers for Disease Control and Prevention website. https://www.cdc.gov/media/
    pressrel/2010/r101022.html. Accessed January 14, 2020.
  5. Macular Edema. National Eye Institute, National Institutes of Health website. http://bit.ly/2MGKMVG. Accessed January 14, 2020.
  6. Vestrum Health Anonymized Electronic Health Record Data.
  7. Holekamp NM. Overview of diabetic macular edema. Am J Manag Care. 2016;22(10 suppl):s284-s291.
  8. Diabetes and Eye Health. American Optometric Association website. http://bit.ly/2YVSGTL. Accessed January 14, 2020.
  9. Bressler NM, Varma R, Doan QV. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(2):168-173.
  10. Data on file. Regeneron Pharmaceuticals, Inc.
  11. Appold K. Subscriber exclusive: tips on managing diabetic patients—developing provider relationships, educating the patient and tracking clinical signs are key. Optom Manag. May 2019. http://bit.ly/2KQPBYZ. Accessed January 14, 2020.